Background Obesity is closely associated with depression and emotional distress. Glucagon like peptide 1 receptor agonists have become widely used for obesity treatment, raising concerns about their potential psychiatric effects. While randomized controlled trials generally report neutral or mildly favorable mood outcomes, real world studies and pharmacovigilance data suggest heterogeneous signals, creating uncertainty regarding psychiatric safety. Aims To critically assess the association between GLP 1 receptor agonist therapy and depressive symptoms in adults with obesity by comparing evidence from randomized trials, real world observational studies, pharmacovigilance databases, and qualitative research published between 2022 and 2025. Methods A narrative review was conducted using PubMed. Original studies involving adults with overweight or obesity treated with GLP 1 receptor agonists and reporting psychiatric outcomes were included. Randomized trials, observational cohorts, pharmacovigilance analyses, and qualitative studies were synthesized narratively due to methodological heterogeneity. Results Randomized controlled trials consistently showed no increased risk of depression or suicidal ideation and, in some cases, modest mood improvement in selected populations without major psychiatric comorbidity. In contrast, real world and pharmacovigilance data revealed heterogeneous findings, including signals of depressive symptoms and anxiety in subsets of patients, limited by confounding and reporting bias. Qualitative evidence demonstrated substantial interindividual variability in emotional responses to treatment. Conclusions Current evidence does not support a causal association between GLP 1 receptor agonist therapy and clinically significant depression in adults with obesity. Discrepancies between data sources are largely attributable to methodological differences and population selection. Individualized assessment and clinical vigilance remain warranted, particularly in patients with underlying psychological vulnerability.